July 31, 2018 06:35 AM EDT
R&D

Ot­su­ka’s $886M-plus drug just flopped in its first cru­cial PhI­II tri­al for front­line AML

John Carroll

Editor & Founder

Five years ago Ot­su­ka swept in and scooped up Cal­i­for­nia-based As­tex for $886 mil­lion, de­ter­mined to get its hands on their promis­ing leukemia drug SGI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times